There are now nearly 15 million children in the United States with obesity, reflecting a steep trajectory over the past few decades that firmly establish it both as a chronic disease and a critical health imperative. In 2023, the American Academy of Pediatrics (AAP) joined other organizations by releasing practice guidelines to emphasize obesity as a chronic disease, not a failure of character or willpower, that is linked to a complex pathophysiology involving energy balance dysregulation and organ system impairment. The new guidelines provide pathways that may include a combination of behavioral changes (eg, nutritious food, ample physical activity) with a choice of FDA-approved agents for managing obesity in adolescents, including semaglutide, liraglutide, orlistat, and phentermine/topiramate ER. Indications for bariatric surgery are also outlined.
This educational webcast titled, Evaluation, Treatment, and Non-Stigmatizing Care for Adolescents with Obesity, will feature expert faculty leading a conversation on how to achieve an equitable, universal approach to treating patients with obesity in the pediatric setting. The discussion will provide learners with a plan to evaluate patients, consider their social determinants of health, initiate appropriate therapies, and monitor treatment. Strategies to implement shared decision-making and other empathetic communications will encourage long-term patient engagement.
Supported by an educational grant from Novo Nordisk, Inc.
Physicians, pharmacists, nurse practitioners (NPs), and physician associates (PAs) specializing in pediatrics.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Golden reports the following financial relationships:
Advisory Board: Acella Pharmaceuticals, LLC; Currax Pharmaceuticals LLC; Gelesis; Lilly; Novo Nordisk; and WW International, Inc.
Consultant: SetPoint Medical
Speakers Bureau: Acella Pharmaceuticals, LLC; Currax Pharmaceuticals LLC; and Novo Nordisk
Other financial or material support: Royalties from Springer
Dr. Stanford reports the following financial relationships:
Consultant: Boehringer Ingelheim; Calibrate Health, Inc.; Currax Pharmaceuticals LLC.; Gelesis; LifeForce; Lilly; Novo Nordisk; Pfizer Inc.; Rhythm Pharmaceuticals, Inc.; Sweetch; Veri Inc.; and Vida Health
Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).